Osteoporosis in Inflammatory Bowel Disease


      Osteoporosis commonly afflicts patients with inflammatory bowel disease, and many factors link the 2 states together. A literature review was conducted about the pathophysiology of osteoporosis in relation to inflammatory bowel disease. Screening guidelines for osteoporosis in general as well as those directed at patients with inflammatory bowel disease are reviewed, as are currently available treatment options. The purpose of this article is to increase physician awareness about osteopenia and osteoporosis occurring in patients with inflammatory bowel disease and to provide basic, clinically relevant information about the pathophysiology and guidelines to help them treat these patients in a cost-effective manner.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.
        World Health Organ Tech Rep Ser. 1994; 843: 1-129
        • Compston J.E.
        • Judd D.
        • Crawley E.O.
        • et al.
        Osteoporosis in patients with inflammatory bowel disease.
        Gut. 1987; 28: 410-415
        • Bjarnason I.
        • Macpherson A.
        • Mackintosh C.
        • et al.
        Reduced bone density in patients with inflammatory bowel disease.
        Gut. 1997; 40: 228-233
        • Pollak R.D.
        • Karmeli F.
        • Eliakim R.
        • et al.
        Femoral neck osteopenia in patients with inflammatory bowel disease.
        Am J Gastroenterol. 1998; 93: 1483-1490
        • Bernstein C.N.
        • Leslie W.D.
        The pathophysiology of bone disease in gastrointestinal disease.
        Eur J Gastroenterol Hepatol. 2003; 15: 857-864
        • Bernstein C.N.
        • Leslie W.D.
        • Leboff M.S.
        AGA technical review on osteoporosis in gastrointestinal diseases.
        Gastroenterology. 2003; 124: 795-841
        • American College of Rheumatology Task Force on Osteoporosis Guidelines
        Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.
        Arthritis Rheum. 1996; 39: 1791-1801
        • van Staa T.P.
        • Leufkens H.G.
        • Abenhaim L.
        • et al.
        Oral corticosteroids and fracture risk: relationship to daily and cumulative doses.
        Rheumatology (Oxford). 2000; 39: 1383-1389
        • van Staa T.P.
        • Leufkens H.G.
        • Cooper C.
        The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.
        Osteoporos Int. 2002; 13: 777-787
        • Neurath M.F.
        • Pettersson S.
        Predominant role of NF-kappa B p65 in the pathogenesis of chronic intestinal inflammation.
        Immunobiology. 1997; 198: 91-98
        • Barnes P.J.
        • Karin M.
        Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases.
        N Engl J Med. 1997; 336: 1066-1071
        • Redlich K.
        • Hayer S.
        • Ricci R.
        • et al.
        Osteoclasts are essential for TNF-alpha-mediated joint destruction.
        J Clin Invest. 2002; 110: 1419-1427
        • Manolagas S.C.
        The role of IL-6 type cytokines and their receptors in bone.
        Ann N Y Acad Sci. 1998; 840: 194-204
        • Schulte C.M.
        • Dignass A.U.
        • Goebell H.
        • et al.
        Genetic factors determine extent of bone loss in inflammatory bowel disease.
        Gastroenterology. 2000; 119: 909-920
        • Boyce B.F.
        • Xing L.
        The RANKL/RANK/OPG pathway.
        Curr Osteoporos Rep. 2007; 5: 98-104
        • Bernstein C.N.
        • Sargent M.
        • Leslie W.D.
        Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study.
        Inflamm Bowel Dis. 2005; 11: 325-330
        • Moschen A.R.
        • Kaser A.
        • Enrich B.
        • et al.
        The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss.
        Gut. 2005; 54: 479-487
        • Hofbauer L.C.
        • Lacey D.L.
        • Dunstan C.R.
        • et al.
        Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells.
        Bone. 1999; 25: 255-259
        • Miheller P.
        • Muzes G.
        • Racz K.
        • et al.
        Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy.
        Inflamm Bowel Dis. 2007; 13: 1379-1384
        • Franchimont N.
        • Putzeys V.
        • Collette J.
        • et al.
        Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.
        Aliment Pharmacol Ther. 2004; 20: 607-614
        • Abreu M.T.
        • Geller J.L.
        • Vasiliauskas E.A.
        • et al.
        Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease.
        J Clin Gastroenterol. 2006; 40: 55-63
        • Ducy P.
        • Zhang R.
        • Geoffroy V.
        • et al.
        Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation.
        Cell. 1997; 89: 747-754
        • Gong Y.
        • Slee R.B.
        • Fukai N.
        • et al.
        LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.
        Cell. 2001; 107: 513-523
        • Mbalaviele G.
        • Sheikh S.
        • Stains J.P.
        • et al.
        Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation.
        J Cell Biochem. 2005; 94: 403-418
        • Ohnaka K.
        • Tanabe M.
        • Kawate H.
        • et al.
        Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts.
        Biochem Biophys Res Commun. 2005; 329: 177-181
        • Adams J.S.
        • Hewison M.
        Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity.
        Nat Clin Pract Endocrinol Metab. 2008; 4: 80-90
        • Silvennoinen J.
        • Lamberg-Allardt C.
        • Karkkainen M.
        • et al.
        Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease.
        J Intern Med. 1996; 240: 285-292
        • Cashman K.D.
        • Shanahan F.
        Is nutrition an aetiological factor for inflammatory bowel disease?.
        Eur J Gastroenterol Hepatol. 2003; 15: 607-613
        • McCarthy D.
        • Duggan P.
        • O'Brien M.
        • et al.
        Seasonality of vitamin D status and bone turnover in patients with Crohn's disease.
        Aliment Pharmacol Ther. 2005; 21: 1073-1083
        • Gilman J.
        • Shanahan F.
        • Cashman K.D.
        Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use.
        Eur J Clin Nutr. 2006; 60: 889-896
        • Duggan P.
        • O'Brien M.
        • Kiely M.
        • et al.
        Vitamin K status in patients with Crohn's disease and relationship to bone turnover.
        Am J Gastroenterol. 2004; 99: 2178-2185
        • Szulc P.
        • Chapuy M.C.
        • Meunier P.J.
        • Delmas P.D.
        Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study.
        Bone. 1996; 18: 487-488
        • Watts N.B.
        • Lewiecki E.M.
        • Miller P.D.
        • Baim S.
        National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist.
        J Clin Densitom. 2008; 11: 473-477
        • Kornbluth A.
        • Hayes M.
        • Feldman S.
        • et al.
        Do guidelines matter?.
        Am J Gastroenterol. 2006; 101: 1546-1550
        • National Osteoporosis Foundation
        Clinician's Guide to Prevention and Treatment of Osteoporosis.
        National Osteoporosis Foundation, Washington, DC2008
        • Lewis N.R.
        • Scott B.B.
        Guidelines for Osteoporosis in Inflammatory Bowel Disease and Coeliac Disease.
        British Society of Gastroenterology, London2007
        • Henderson S.
        • Hoffman N.
        • Prince R.
        A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.
        Am J Gastroenterol. 2006; 101: 119-123
        • Palomba S.
        • Manguso F.
        • Orio Jr, F.
        • et al.
        Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
        Menopause. 2008; 15: 730-736
        • Chestnut 3rd, C.H.
        Calcitonin in the prevention and treatment of osteoporosis.
        Osteoporos Int. 1993; 3: 206-207
        • Rossouw J.E.
        • Anderson G.L.
        • Prentice R.L.
        • et al.
        Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.
        JAMA. 2002; 288: 321-333
        • Delmas P.D.
        • Bjarnason N.H.
        • Mitlak B.H.
        • et al.
        Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
        N Engl J Med. 1997; 337: 1641-1647
        • Ettinger B.
        • Black D.M.
        • Mitlak B.H.
        • et al.
        Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trialMultiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
        JAMA. 1999; 282: 637-645
        • Neer R.M.
        • Arnaud C.D.
        • Zanchetta J.R.
        • et al.
        Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
        N Engl J Med. 2001; 344: 1434-1441
        • Vestergaard P.
        • Rejnmark L.
        • Mosekilde L.
        Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures.
        Calcif Tissue Int. 2008; 82: 249-257
        • Schoon E.J.
        • Bollani S.
        • Mills P.R.
        • et al.
        Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.
        Clin Gastroenterol Hepatol. Feb 2005; 3: 113-121
        • Reffitt D.M.
        • Meenan J.
        • Sanderson J.D.
        • et al.
        Bone density improves with disease remission in patients with inflammatory bowel disease.
        Eur J Gastroenterol Hepatol. 2003; 15: 1267-1273
        • Ryan B.M.
        • Russel M.G.
        • Schurgers L.
        • et al.
        Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study.
        Aliment Pharmacol Ther. 2004; 20: 851-857
        • Pazianas M.
        • Rhim A.D.
        • Weinberg A.M.
        • et al.
        The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease.
        Ann N Y Acad Sci. 2006; 1068: 543-556